Evidence map›Paper›PMID 28008779›Full record

Trial reportIntegrative cancer therapies2018

The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.

Shreya Tocaciu, Lesley J Oliver, Ray M Lowenthal, Gregory M Peterson, Rahul Patel, Madhur Shastri, Georgia McGuinness, Inger Olesen, J Helen Fitton

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Integrative cancer therapies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. The Effect ofNutrients · 2022
    Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Anticancer Mechanism ofPharmaceuticals (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Fucoidan, a brown seaweed polysaccharide in nanodrug delivery.Drug delivery and translational research · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Perspectives for the Use of Fucoidans in Clinical Oncology.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shreya Tocaciu1 Royal Hobart Hospital, Hobart, Tasmania, Australia.
Lesley J Oliver1 Royal Hobart Hospital, Hobart, Tasmania, Australia.
Ray M Lowenthal2 University of Tasmania, Hobart, Tasmania, Australia.
Gregory M Peterson2 University of Tasmania, Hobart, Tasmania, Australia.
Rahul Patel2 University of Tasmania, Hobart, Tasmania, Australia.
Madhur Shastri2 University of Tasmania, Hobart, Tasmania, Australia.
Georgia McGuinness2 University of Tasmania, Hobart, Tasmania, Australia.
Inger Olesen3 Andrew Love Cancer Centre, Barwon Health, Geelong, Victoria, Australia.
J Helen Fitton4 Marinova Pty Ltd, Cambridge, Tasmania, Australia.
University of Tasmania · AURoyal Hobart Hospital · AUBarwon Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the use of complementary and alternative medicines is widespread in cancer patients, clinical evidence of their benefits is sparse. Furthermore, while they are often assumed to be safe with regard to concurrent use of anticancer therapies, few studies have been carried out to investigate possible interactions. Fucoidans are a group of sulfated carbohydrates, derived from marine brown algae, which have long been used as dietary supplements due to their reported medicinal properties, including anticancer activity. The aim of this study was to investigate the effect of co-administration of fucoidan, derived from Undaria pinnatifida, on the pharmacokinetics of 2 commonly used hormonal therapies, letrozole and tamoxifen, in patients with breast cancer.

methodsThis was an open label non-crossover study in patients with active malignancy taking letrozole or tamoxifen (n = 10 for each group). Patients took oral fucoidan, given in the form of Maritech extract, for a 3-week period (500 mg twice daily). Trough plasma concentrations of letrozole, tamoxifen, 4-hydroxytamoxifen, and endoxifen were measured using HPLC-CAD (high-performance liquid chromatography charged aerosol detector), at baseline and after concomitant administration with fucoidan.

resultsNo significant changes in steady-state plasma concentrations of letrozole, tamoxifen, or tamoxifen metabolites were detected after co-administration with fucoidan. In addition, no adverse effects of fucoidan were reported, and toxicity monitoring showed no significant differences in all parameters measured over the study period.

conclusionsAdministration of Undaria pinnatifida fucoidan had no significant effect on the steady-state trough concentrations of letrozole or tamoxifen and was well tolerated. These results suggest that fucoidan in the studied form and dosage could be taken concomitantly with letrozole and tamoxifen without the risk of clinically significant interactions.

Indexed as

Antineoplastic AgentsBreast NeoplasmsNitrilesTamoxifenTriazolesUndariaAdministration, OralAdultAgedAntineoplastic Agents, HormonalFemaleHerb-Drug InteractionsHumansLetrozoleMiddle AgedPhytotherapy4-hydroxy-N-desmethyltamoxifenafimoxifeneAntineoplastic AgentsAntineoplastic Agents, HormonalfucoidanLetrozoleNitrilesPolysaccharidesTamoxifenTriazolesCAMclinical trialcomplementary medicinesdrug interactionsfucoidanletrozoletamoxifenUndaria

Identifiers

PMID28008779
PMCPMC5950942
OpenAlexW2578796448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.